Skip to main content
Premium Trial:

Request an Annual Quote

Arrowhead Releases White Paper on Newly Acquired siRNA Delivery Technology


Arrowhead Research this week released a white paper detailing the dynamic polyconjugate siRNA-delivery technology it picked up through its recent acquisition of Roche's RNA therapeutics assets.

"Studies in non-human primates have shown that [dynamic polyconjugates, or] DPCs, are highly effective and have safety margins well beyond those currently achievable by other systems,” Arrowhead President and CEO Christopher Anzalone said in a statement. “Moreover, the modular nature of DPC technology and its ability to optimize individual components within the same polymer provide the potential to target all types of cells.”

The white paper can be found here.

The delivery technology was originally developed by Mirus Bio, which Roche acquired in 2008 for $125 million (GSN 7/24/2008).

Despite this and additional investments in RNAi, Roche announced about two years later that it was halting all of its in-house research and development on the gene-silencing technology as part of a broader restructuring effort (GSN 11/18/2010).

Last month, Arrowhead disclosed that it had signed a deal acquiring these assets from Roche in exchange for roughly 10 percent of its stock and million-dollar late-stage milestones (GSN 10/27/2011).

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.